Atlas Trials

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

Clinical trial NCT03616886 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03616886
Sponsor
Jules Bordet Institute
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2018-12-28
Primary completion
2025-03-01
Enrollment
129

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.